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Abstract
Coronary artery disease can be treated by implanting a stent into the blocked region
of an artery, thus enabling blood perfusion to distal vessels. Minimally invasive proce-
dures of this nature often result in damage to the arterial tissue culminating in the
re-blocking of the vessel. In an effort to alleviate this phenomenon, known as reste-
nosis, drug eluting stents were developed. They are similar in composition to a bare
metal stent but encompass a coating with therapeutic agents designed to reduce
the overly aggressive healing response that contributes to restenosis. There are many
variables that can influence the effectiveness of these therapeutic drugs being trans-
ported from the stent coating to and within the artery wall, many of which have
been analysed and documented by researchers. However, the physical deformation
of the artery substructure due to stent expansion, and its influence on a drugs ability
to diffuse evenly within the artery wall have been lacking in published work to date.
The paper highlights previous approaches adopted by researchers and proposes the
addition of porous artery wall deformation to increase model accuracy.
Introduction
Atherosclerosis is a degenerative disease that affects coronary, carotid and other per-
ipheral arteries in the body. Disease formation can occur as early as childhood with
the development of fatty streaks within the artery wall. As the aging process progresses
these fatty streaks accumulate becoming larger lipid deposits within the artery and are
detrimental to the smooth operation of the vasculature. Occlusions ensuing from
aggressive plaque progression can often culminate in an ischemic attack, such as an
apoplectic attack or a myocardial infarction [1-3]. There are a number of interventional
procedures available to the clinician but the successful emergence of drug eluting
stents (DES) has seen them become the preferred choice, so much so that by the
beginning of 2006 more than 8 out of 10 coronary stents were DES [4] at a cost of
between $4 and $5 billion annually [5].
When used in conjunction with balloon angioplasty, a bare metal stent increases post
procedural patency by acting as a scaffold for the artery wall. Stenting however causes
arterial injury resulting in the restenosis of a large portion of stented arteries. In an
attempt to reduce the number of patients that warranted re-interventional procedures,
stents were coated with therapeutic agents to combat restenosis and became known as
DES. Drug loaded polymer coatings on the stent surface treat the injuries inflicted on
the artery wall upon stent implantation. Once these drugs are within the wall they act
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against the arteries natural healing mechanisms in order to reduce the possibility of a
recurring blockage. Quite often, when a DES is implanted in an artery a portion of the
drugs used to target restenosis are washed away in the blood stream. Therefore it is
imperative to understand all of the mechanisms that influence drug transport from the
device so that DES can be designed to optimise their capabilities. This study began by
defining the current knowledge base pertaining to drug transport within the artery wall
from DES. However, the fundamental aspect concerning the mechanical deformation
of the porous artery wall, and its influence on drug concentrations within, had not
been reported in computational DES studies to date.
Coronary artery disease
Coronary artery disease (CAD) has been intrinsically linked to atherosclerosis since the
early 20th century [1,6-8] and refers to the localisation of disease within the coronary
arteries. CAD is the foremost cause of mortality in the world’s industrialised nations
[2,8-13] and is responsible for approximately 700,000 deaths in the United States of
America annually [2,10]. Regular exercise and a balanced diet have been shown to
influence CAD development but it is the concentration of lipid rich cholesterol in the
blood that is considered the most important factor [8,14-18].
There are a number of ways to treat CAD such as coronary artery bypass graft
(CABG) surgery. Although the long term patency rates of these grafts are moderate,
CABG surgery remained the gold standard in the treatment of CAD until 1977 when
the first percutaneous transluminal coronary angioplasty (PTCA) surgery was per-
formed [19,20]. It was discovered that a substantial percentage of patients, reported to
be between 30 and 60%, experienced recurrent ischemia due to the re-blocking of the
artery (restenosis) within 6 months after PTCA. Restenosis is attributed to the
mechanical injury caused by over dilating a device within the vessel resulting in neoin-
timal hyperplasia, elastic recoil and negative arterial remodelling [4,19-26]. The next
major advance in the field of minimally invasive interventional cardiology came in the
form of the coronary artery stent (CAS). CAS reduced failure rates to between 10 and
40% [4,7,9,13,19-23,25,27-31] because it virtually eliminates elastic recoil and negative
remodelling of the artery [32,33].
Restenosis and its mechanisms
Restenosis can best be described as an overly aggressive inflammatory healing response
in the artery wall due to the mechanical injury inflicted by balloon expansion. It is
quantified by the reduction of lumen size after an intravascular interventional proce-
dure [34]. Inflation of a balloon catheter within a diseased artery pushes the plaque
against the artery wall, forcing the artery to stretch and often results in the fracture of
not only the plaque but in some cases can damage the artery wall also [32,35]. Similar
damage ensues when a stent is used in conjunction with a balloon catheter, however a
stent can cause excessive injury, increasing neointimal formation, by penetrating the
media and in extreme cases going as deep as the adventitial layer of the artery [22,32].
The development of restenosis can be influenced by three processes after PTCA,
namely elastic recoil, arterial negative remodelling and neointimal hyperplasia
[7,19,21-23]. Restenosis in up to 60% of patients undergoing PTCA can be attributed
to the extent of elastic recoil and arterial modelling. Elastic recoil can occur within 1
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hour of PTCA and is attributed to the passive recoil of the elastic medial layer of the
artery. Positive remodelling of the artery wall occurs naturally in atherosclerotic
arteries as a compensatory response to plaque formation and limits the narrowing of
the vessel lumen. There are contrasting opinions on the mechanisms behind arterial
remodelling [19] but the negative remodelling of the artery demonstrated after PTCA
has been shown to contribute to restenosis by narrowing the artery. Both elastic recoil
and arterial modelling are believed to be virtually eliminated when angioplasty is used
in conjunction with a stent. Neointimal hyperplasia occurs in response to arterial
injury, whereby platelets and fibrin are deposited on the wound. Growth factors are
consequently released from the platelets which can promote smooth muscle cell
(SMC) migration from the media. The result of this is a build up of SMC, extracellular
matrix (ECM) and macrophages at the injured site over several weeks. It is here that
cellular division takes place which appears to be essential for the development of reste-
nosis [4,19,22,24,32,33,36-39]. Reduction of SMC proliferation is of the utmost impor-
tance if the incidence of restenosis is to be reduced [18,21,22,27,37, 40,41]. The second
generation of stent, the DES family, was developed with a coating of anti-restenotic
agents aimed at alleviating the initiation of SMC proliferation to the site of injury after
stent implantation.
Drug eluting stents
Long term clinical trial results for this technology are not widespread, although several
studies have reported on the performance of these devices in coronary arteries in the
short to medium term. Some trials have indicated that the incidence of myocardial
infarction and death are lower when DES are used [42,43] while other studies suggest
that DES and BMS perform similarly [44]. The contrasting outcomes from such trials
raise questions regarding the effectiveness of DES which has resulted in an increased
effort by researchers to develop a means of predicting the behaviour of these devices
in the short to long term.
As the primary use of these devices to date has been in the coronary arteries, this
application will form the focus of the information presented. Mechanically speaking,
stents offer far superior structural support than PTCA but the adverse biological
responses need to be understood in order to address the mechanisms of injury that
lead to restenosis. As described above, it is generally accepted that one of the main
causes of restenosis following bare metal stent (BMS) implantation is SMC prolifera-
tion and migration from the media to the injured site. Thus, the curtailment of this
excess SMC proliferation has been identified as the focal point in combating restenosis
[18,21,22,27,37,40,41]. Attempts at systemic drug delivery to inhibit restenosis after
stenting failed because effective dosing levels had a toxic effect and could not be toler-
ated by the patients [22,45]. Therefore the concept of local drug delivery using a sent
platform was developed in an attempt to redress this. The site specific local delivery of
drugs from DES offers an advantage over systemic delivery because the drug is applied
to the injured vessel at the exact location and time that damage occurs.
The anti-restenotic coating on a DES inhibits the formation of neointimal hyperpla-
sia by suppression of the inflammatory reaction, platelet activation and SMC prolifera-
tion. Most of the drugs explored originally were used as agents for anti-transplant
rejection or as immunosuppressive drugs [21,46]. In April 2003 the first DES to gain
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commercial approval from the Food and Drug Administration (FDA) in the United
States was the Cypher™ stent, which was developed by Cordis Corporation (Miami, FL.
USA) and used a drug called sirolimus. Boston Scientific’s (Natik, MA. USA) Taxus™
family of stents were the second DES platform approved by the FDA in March of the
following year. The drug employed on the Taxus stent was called paclitaxel [47]. These
first generation DES had a profound effect on reducing restenosis rates compared to
BMS models. Clinical trials carried out on the Cypher stent (SIRIUS-1) showed reste-
nosis rates of 8.9% after 8 months compared to 36.6% for BMS in the same study.
Likewise the TAXUS IV trials heralded a dramatic reduction in restenosis rates when
compared to BMS after 9 months, 7.9% versus 26.6% respectively [47].
In 2008, results were published from the SPIRIT-III clinical trials comparing Abbott
Vascular’s next generation everolimus DES, the Xience-V, with Boston Scientific’s
Taxus Express2 paclitaxel DES. The trial suggested that angiographic in-segment late
loss was significantly less for the Xience-V stent than for the Taxus Stent. The trial
also showed a dramatic reduction in major adverse cardiac events for the Xience-V
stent compared to the Taxus stent, recording a 43.2% and 41.7% reduction after 9 and
12 months respectively [30]. Reasons for this may be the allocation of drug type or the
design of the stent and its impact on the artery wall.
Arterial mass transport
Mass transport (MT) refers to the transfer of mass, i.e. the species of interest which is
drugs in the case of DES, from regions of high concentration to low concentration. In
the absence of a free flowing system the presence of these concentration gradients
induces diffusion, e.g. between the DES and the artery wall. MT can be broken up into
two types within the human vasculature. Firstly blood side MT (BSMT) refers to spe-
cies transport within the vessel lumen and is subject to the haemodynamics therein.
The flowing nature of blood within the lumen will limit the DES ability to deliver ther-
apeutic quantities of drug to the wall via BSMT, as it effectively washes the drugs away
from the injured area. It is only in regions of high blood flow recirculation, e.g. imme-
diately behind a stent strut, that it is possible for a sufficient amount of drug to remain
for long enough to result in a therapeutic response.
The second mode is in relation to transport within the wall of the artery, referred to
as wall side MT (WSMT). Along with the properties of the species being transported
within the artery wall, WSMT depends on the structural condition of the wall itself, i.
e. a damaged intimal layer could facilitate accelerated MT through to the medial layer
[48]. The accurate modelling of MT within the artery wall requires a keen knowledge
of the arterial substructure. Although a pressure induced velocity exists across a
healthy artery wall, DES are implanted in arteries that are heavily blocked and in war-
rant of intervention. If the plaque were dense enough the transmural velocity would
reduce to approximately zero. This would reduce the Peclet number and indicate a dif-
fusion dominated mass transport environment within the artery wall.
The arteries themselves are not simply cylindrical mono-layered vessels. The wall
consists of a complex multilayer porous substructure with the interstitial areas com-
prising predominantly of plasma. In a healthy artery this substructure (figure 1) is
comprised of three concentric layers; the tunica intima, the tunica media and the
tunica adventitia. The tunica intima is the innermost layer, comprising of a single layer
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of endothelial cells and a subendothelial layer mainly consisting of delicate connective
tissues and collagen fibres. The outer boundary of the tunica intima is surrounded by
an elastic tissue with fenestral pores known as the internal elastic lamina (IEL) [49].
The medial layer consists primarily of concentric sheets of SMC and elastic connective
tissue. This configuration of SMC sheets enable the artery wall to contract and relax.
The tunica media and the tunica adventitia are separated by another thin band of elas-
tic fibres known as the external elastic lamina (EEL). The outermost layer of the artery,
the tunica adventitia, comprises of connective tissue fibres and some capillaries. These
fibres blend into the surrounding connective tissues and aid in stabilising the arteries
within the body [17,49,50]. However, DES are deployed in arteries that have a signifi-
cant amount of plaque which will undoubtedly have a bearing on arterial MT out-
comes. The stenting procedure itself will also have an impact on MT due to the
damage caused to the intimal layers upon stent deployment and subsequent thrombus
build up around the stent. The greater the volume of clot that surrounds the strut,
without being debilitating to blood flow, and the closer the strut is to the artery wall,
provokes more optimal conditions for arterial MT.
Computational studies can give us vital information regarding the MT capabilities of
a DES. Once the artery has been adequately defined changes can easily be made to
computational models in order to assess their impact on the stents performance.
Figure 1 Artery wall structure.
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Parameters such as the degree of artery wall damage and strut embedment, drug type,
polymer characteristics and the extent and type of disease are documented in the fol-
lowing section. Although these studies give us an insight as to the behaviour of these
variables, no published work to date contains a complete computational DES MT
model because they all fail to incorporate the influence of the stent compressing the
porous artery wall.
Computational research
Spatial fluctuations in arterial drug concentration will depend on a host of variables
such as the drug and polymer characteristics, stent design and also the structure of the
artery wall and the plaque encased therein. Computational prediction of drug mass
transport from a DES is a powerful means of evaluating the effectiveness of stent
design before a stent is taken to clinical trial. This provides the manufacturer with a
level of controllability, enabling the production of a DES that will offer sufficient
dosage of therapeutic agents to the injured vessel while reducing the possibility of toxi-
city in locations of greater stent arterial coverage, e.g. at strut junctions.
The theoretical description and subsequent computational representation of mass
transport from a DES into the artery wall presents significant challenges to researchers
due to the complex interactions of all the physical and chemical processes taking
place. Therefore it is necessary to make simplifications and assumptions in order to
represent arterial MT and solve the problem computationally. One such simplification
is to neglect the intimal layers of the artery, although they are known to effect species
uptake within the wall. They are often neglected under the assumption that they
become denuded upon stent implantation, leaving the stent strut in direct contact with
the medial layer. This assumption is commonplace because it is the drug distribution
within the medial layer that is ultimately responsible for reducing restenosis. From a
computational perspective one of the more common ways to reduce the demand on
numerical solvers is to decrease the degrees of dimensionality of the system from 3-D
to 2-D and finally a 1-D analysis if need be.
In 2008, Zunino et al. [51] developed a comprehensive representation of a DES
within an artery. The computational model was 3-D in nature and analysed the stent
from a mechanical (upon balloon expansion) to a fluid dynamic (blood flow over the
stent struts) perspective. A number of stent strut cells were modelled in contact with
the artery and the concentration distribution was analysed. Reducing a models dimen-
sionality saves on computational demands but not necessarily at the expense of realis-
tic representation. Balakrishnan et al. published work [52-54] which demonstrated the
progression of their 2-D computational DES transport model. The 2-D computational
model presented in their most recent publication [52] may be perceived to be more
realistic than the 3-D one proposed by Zunino et al. [51] due to the consideration of
mural thrombus surrounding the stent struts. Likewise 1-D MT analysis can be effec-
tive in quantifying drug concentrations within the wall. Although dimensionally infer-
ior, the work of Pontrelli and de Monte [55] describe MT through multiple layers, a
porous artery medial layer and a porous polymer coating with polymer top coat (simi-
lar in composition to the Cypher stent [56]). The application of a porous artery wall
subdomain is more representative of an actual artery wall than the homogeneous walls
modelled in the aforementioned 2-D and 3-D examples.
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Influence of drug type on mass transfer
The hydrophobicity of drugs plays an important role in local drug concentrations from
stents [48]. Hydrophilic drugs were found to wash away more quickly due to their ten-
dency to follow transmural fluid movement, while hydrophobic drugs can attain higher
concentrations in the artery wall due to their preferential binding to artery wall struc-
tural proteins. Hydrophilic drugs, such as heparin, were initially sought as the answer
to combating restenosis but proved unsuccessful due to lower heterogeneous tissue
concentrations than hydrophobic drugs. In contrast, drugs of a hydrophobic nature,
such as paclitaxel and sirolimus, are advantageous due to their retention of high thera-
peutic doses within the wall [48]. Hwang et al. [48] suggest that diffusion in the media
was anisotropic, with the circumferential diffusion being approximately 10 times
greater in magnitude than the transmural value. In 2004, Zunino [57] conducted a
numerical analysis comparing the employment of contrasting drug types, heparin and
taxus. Heparin diffusivity within the wall was almost 3 times that of taxus. It was
found that taxus accumulated more easily than heparin in the region surrounding the
strut because of its tendency to bind with the tissue and its lower diffusivity. Zunino
[57] recorded a 70% loss of heparin into the blood after 6 hours while for the same
time period only 60% was lost for the taxus simulation.
Instead of attributing drug specific diffusion values in their analysis some researchers,
such as Mongrain et al. [31], describe the concentration distribution in the artery wall
for a range of arbitrary diffusion values. Their results indicate that the amount of drugs
that accumulate within the artery wall depend on the values of the diffusion coefficient
in the wall and the polymer respectively. Similar to Zunino [57], Mongrain et al. [31]
deduced that drug accumulation within the wall was greater for smaller artery wall diffu-
sivities as this reduces the drugs ability to leave the artery wall once embedded.
Influence of strut positioning on mass transport
Strut positioning within an artery will ultimately be responsible for local fluctuations in
arterial drug concentration. Unlike some of the first generation stents, with their uni-
formly distributed strut arrangement, the newer stents have irregular cell designs that
enable greater flexibility while retaining structural stability. This generally results in an
inhomogeneous distribution of stent struts in the circumferential and longitudinal
directions. Hwang et al. [48] examined the effect of strut placement on a circumferen-
tial artery cross section (comparing 8 evenly with 8 randomly placed struts). Although
mean tissue concentration remained the same regardless of strut position, the local
concentrations, which predominantly determine biological response, are heavily depen-
dent on strut spacing. Balakrishnan et al. [54] investigated the influences of multiple
struts, strut spacing and the incidence of overlapping stent struts in a 2-D longitudinal
artery cross section. A concentration of unity was placed on the stent surface and no
polymer was used, although this is not ideal it does give a good approximation of the
effect of the aforementioned variables after stent implantation. The highest wall
concentration for longitudinal strut distribution was witnessed where the struts were
closest together (1 strut length spacing apart), while a gap of 7 strut lengths resulted in
individual peaks in concentration under each strut that increased slightly along the
length of the model. For the case of overlapping struts, twice as much drug is available
in close proximity and the flow around the struts is altered. Balakrishnan et al. [54]
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discovered that peak concentrations resulting from different overlapping strut
configurations rise by 22-34% compared to the single strut case. The incidence of over-
lapping struts where one of them was fully embedded within the wall resulted in an
increase of 45% in peak concentration. Mongrain et al. [31,58] conducted more thor-
ough research relating to strut embedment and its effect on concentration within the
wall. Degree of strut embedment was found to play a significant role in arterial con-
centration within the first 3 days of deployment. At 250 μm beneath the endothelium
significantly higher concentrations were witnessed directly beneath any single strut
compared to levels measured half way between two struts at the same depth. The
study showed that after 3 days the wall concentrations normalised at both points due
to the reduction of drugs being released from the polymer coating [31].
Influence of polymer type on mass transport
Stent coatings play a vital role in the regulation of drug release from within. Careful
consideration must be observed when allocating a polymer as a drug carrier for a DES.
In this study the design of polymer coatings is not discussed in detail as these designs
will ultimately only contribute to the diffusivity value of the drugs from the device.
The following section reviews how varying polymer drug diffusivity (a consequence of
polymer coating design) affects mass transport. If the polymer is not biocompatible an
inflammatory response ensues [22,46] and in certain cases the development of intimal
hyperplasia can be doubled when uncompatable polymers are used compared to a con-
trolled substance [23]. Each biologically viable polymer must also be able to endure the
stresses exerted with stent deployment in the arteries and must be able to resist crack-
ing and peeling. They also have to maintain their physiochemical properties after steri-
lisation. There have been numerous polymers suggested as possible suitors for storing
drugs on a DES but most of the polymers actually used on commercial DES are
proprietary. Drug release rates can be altered with the addition of an extra layer of
covering polymer to modulate between slow and fast release formulations. This adds
an extra degree of complexity when designing functional DES.
Mongrain et al. [31,58] analysed how drug diffusivities within the polymer coating
can impact drug concentration within the artery wall. While lower effective drug diffu-
sivity values in the artery wall are favourable for uptake within the wall, having a low
drug diffusivity in the polymer can be just as influential on the outcome. After 3 days
an arterial concentration of 30.51% was achieved when the drug diffusivity in the poly-
mer (Dpolymer) was 1 × 10
-14m2/s but when Dpolymer was increased to 1 × 10
-12m2/s the
arterial concentration reduced to 3.55% (in both cases Dwall was 1 × 10
-14m2/s). Balak-
rishnan et al. [53] reiterates this finding but there are optimal polymer diffusivities that
promote favourable arterial drug concentrations. At the extremes of drug diffusivity in
the polymer coating, drug can be released so rapidly that it exceeds tissue absorption
rate and the majority of drug can be lost to the blood stream. On the other hand if the
drug is released too slowly it will not effectively penetrate the artery wall at levels
sufficient to be therapeutic. The influence of dose and polymer thicknesses on the drug
distribution within the wall was demonstrated by Balakrishnan et al. [53]. Drug release
from thinner coatings with high concentrations was predicted to be fast initially but sub-
ject to a rapid decline when compared to a thicker polymer coating with lower
concentration.
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Balakrishnan et al. [53] and Mongrain et al. [31,58] modelled their stent struts with a
polymer matrix coating in which the drug is uniformly dispersed (figure 2A). The drug
molecules further away from the surface have a longer migration distance, resulting in
a lower drug release rate over time [56]. This type of configuration can be seen on
Boston Scientific’s Taxus™ stents. Another popular method of controlled release is a
reservoir coating (figure 2B) as seen on Cypher™ stent developed by Cordis. In this
configuration the stent is coated with a drug loaded base coat while a thin top coat
acts as a rate controlling membrane [56]. Varying the diffusivity of the top coat regu-
lates the transition of drug from the base coat to the artery wall.
Influence of thrombus on mass transport
Hwang et al. [59] were among the first to explore the influence of thrombus height,
width and type on the arterial drug uptake. Stents are often deployed at sites of throm-
bus and after implantation a clot will inevitably develop once the struts become cov-
ered with plasma proteins. In most cases this will not be angiographically present or
clinically evident but even a fine layer of clotting blood deposited on the surface of the
DES can alter drug distribution within the wall. The presence of clot alters the local
environment of the stent strut and the physiological transport forces that regulate
arterial uptake and retention. Late stent thrombosis has been reported to occur at a
rate of 0.6% each year after DES implantation for up to 3 years [52] and strut position
within any clot will have a major influence on the arterial uptake. The greater the
mass of clot over the strut and the closer the strut is to the wall tends to provoke
more optimal conditions for drug delivery. Hwang et al. [59] discovered that in this
configuration concentration distribution in the wall can be 30 fold higher than situa-
tions where no clot is present. Similarly thrombus clots between the strut and the
artery wall act as a buffer layer and reduce wall concentrations. Clot diffusivities higher
than that of the arterial tissue can result in drug transfer from the stent to the artery
wall at a rate faster than the wall can absorb. This results in the undesirable loss of
drug to the circulatory system. Clots with diffusivities equal to or lower than the arter-
ial wall transport drugs to the wall at a rate where the wall can effectively absorb the
drugs, thus reducing drug loss to the bloodstream.
Figure 2 Drug eluting stent strut cross-sections. A) is a DES strut with a drug loaded polymer matrix
and stent strut B) has a transport regulating topcoat.
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In 2008, Balakrishnan et al. [52] assessed how variations in mural thrombus size and
distribution contribute to fluctuating arterial drug intensities. Their simulations indi-
cate that thrombus cannot influence the slow rate of drug release from the stent
because the polymer resistance to drug transport is significantly greater than that of
the thrombus, which is consistent with in vivo experimental drug release. Local throm-
bus, just covering the strut, of 0.1 mm2 increased peak average drug concentration and
cumulative exposure by 80%. Greater clot formation between stent struts will also have
an effect on arterial concentrations because once the species is transported within the
clot it effectively increases the surface area from which the artery wall can absorb
drugs. The formation of this interstrut thrombus, described as diffuse thrombus, acts
as a shield from drug washout and culminates in an increase in arterial concentration
by up to 3.5-fold [52].
The variability of thrombus can have a major impact on arterial drug concentrations.
It can aid in drug uptake and retention within the wall when it covers the stent but
too much thrombus will effectively block the artery, thus creating a problem that the
DES aimed to alleviate. Also it can act as a barrier in preventing drugs from reaching
the wall when it is located between the stent strut and the wall. The likely scenario fol-
lowing DES implantation within the vasculature is that at some location along the
length of the stent each of these situations will be present. A computational approach
considering variations in thrombus formation along the length of a stent would provide
insight into resulting variations in arterial drug concentrations therein.
Porous media
Drug transport within the vasculature is predominantly dependent on diffusion and
convection. The haemodynamic nature of blood within the lumen results in convection
dominated transport, while MT within the porous wall is heavily reliant on diffusion.
The ratio of convective to diffusive forces is calculated by the Peclet number, Pe = vL/
D, where v, L and D are the fluid velocity, characteristic length and species diffusivity
respectively. Physiological Peclet numbers range typically from 0.1 to 10. A small Pe
(i.e. Pe << 1) is representative of transport which is dominated by diffusion, while a
higher Pe (i.e. Pe >> 1) indicates convection dominated MT [50].
MT within the artery wall was studied in detail prior to the advent of stent based
drug delivery devices in 2003. In 2002, Stangeby and Ethier [6] analysed the transport
of macromolecules, such as low density lipoproteins (LDL), from the lumen through
the endothelium and into the wall of a stenosed artery section. Subsequent research
from Yang and Vafai [60] examined the effects of hypertension on LDL transport
across each layer of the artery wall. In 2004, Tada and Tarbell [61] investigated the
effects that the IEL has on macromolecule transport through the wall. Tada and Tar-
bell [61] took a more microscopic perspective of the artery wall than the others by
modelling individual SMC. Although each of these studies differ somewhat, one thing
they have in common is that the artery wall is treated as a porous structure. This
approach may be applicable in cases of MT from a DES. DES are deployed in diseased
arteries, a result of which is severely compromised artery wall filtration velocities. The
resulting decrease in the Peclet number will reveal that MT is diffusion dominated in
the artery wall. That is not to say the porous classification of the artery wall is no
longer relevant when analysing MT from a DES. In fact the porous nature of any
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material, biological or otherwise, will ultimately determine the diffusion rates within
the structure. Therefore any change in the structure of a porous media will alter its
diffusion characteristics, as is the case for a stent expanding against an artery wall.
In previous computational studies that analyse the MT of drugs from stents only a few
treat the artery wall as porous [48,55,57]. In all published research to date, to the best of
the researchers’ knowledge, the change in the structure of the artery wall under stent com-
pression and its subsequent effect on drug MT have not been modelled computationally.
However O’Connell and Walsh [62] have demonstrated this effect in an analogous porous
material, which indicates that artery wall compression should be present in all DES com-
putational models. Stent strut thickness may be vital in minimising the extent of arterial
compression after DES expansion. The results from the recent SPIRIT-III clinical trials
[30] could be an indication of the influence of strut thickness on arterial drug distribution
and hence the ability to combat restenosis. It may be possible to develop a computational
drug transport model based on these findings, thus creating a DES for optimal arterial
MT. A reported difference of 60 μm in strut thickness between two different stents used
in the SPIRIT-III trial may not necessarily result in 60 μm further compression due to
the elastic nature of the artery. However an exploration into the extent of compression on
the artery wall due to stenting would exhibit changes in arterial diffusivity compared to
the case of a relaxed artery [62]. This can be attributed to a reduction in porosity coupled
with an increase in tortuosity (equation 1) within the artery wall beneath the stent strut.
The result of this relationship, described in equation 2, is an overall reduction in the effec-
tive diffusivity of drugs within the artery wall.
Structural influence of arteries on mass transport
The structure of an artery is unique in that it enables uninterrupted blood flow through-
out the body, providing the nutrients required for everyday function. For example its
elastic nature enables it to contract and expand under pulsatile conditions induced from
a beating heart. Along with a healthy endothelial layer to regulate species progression to
the wall, the transport of such species once within the wall is influenced by the structure
therein. A change in this structure will subsequently alter how the species are trans-
ported. When a stent is implanted within an artery it has a major impact on the struc-
ture of the wall. Differences in stent design will contribute to this because under similar
balloon expansion criteria a thicker stent strut will result in greater compression of the
artery wall. In the SPIRIT-III clinical trials, the Xience-V stent is 60 μm thinner than its
Taxus counterpart and could be a factor behind its clinical success thus far. The thinner
struts would cause less compression on the artery wall which in turn would better aid
drug MT. Considering that the medial layer of the artery wall is only approximately
200 μm thick, any reduction in changes to its integrity could yield positive results. How-
ever greater radiopacity and structural support is achieved with a thicker strut [63].
Arterial properties such as permeability (K), porosity (ε), tortuosity (τ) and diffusivity (D)
dictate the transport of drugs within the respective wall layers. The compression of these
layers will alter these properties which in turn may inhibit the transport of species as gov-
erned by the MT equations. The permeability of a material is essentially its ability to per-
mit the transfer of fluid through it. Permeability ultimately depends on the porosity and
tortuosity of the artery wall and reducing it through wall compression following stent
implantation compromises the arteries’ ability to permit transport of drug.
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Porosity (ε) is a dimensionless parameter and is the ratio of pore volume to the total
material volume. Any porous material under compression will demonstrate a smaller
pore ratio than that of its relaxed state. This in turn influences the tortuosity (τ) as
described by the pore path through the material. As the tortuosity increases so too
does the effective distance over which diffusion has to take place [64]. It can be esti-
mated by the arc-chord ratio, equation 1, which is the ratio of the actual pore length




The structure of the artery wall is highly heterogeneous and different layers will have
different diffusivities. But the heterogeneity of these layers is highly regular and as such
can be lumped into an effective diffusion parameter that characterises bulk drug trans-
port within each respective artery layer [65]. Diffusion is caused by random molecular
motion that eventually leads to complete mixing without the interaction of external
forces. However, in a porous media diffusion takes place in confined tortuous pores
and its progression is impeded as the tortuosity increases while the porosity decreases.
The effect of pore size coupled with the tortuous nature of the arterial layers results in
an effective diffusion (Deff) coefficient individual to each of its constituent layers and




where DFree is the free diffusivity and can be described by the Stokes-Einstein equa-






Figure 3 Determination of tortuosity through a porous material using the arc-chord ratio. The
tortuosity of a path through a porous structure (A) can be determined by the ratio of the pore length, L,
to the displacement, X. As can be seen in (B) and (C), the magnitude of L remains constant but as the
compression increases the displacement X reduces to X’ which results in an increase in tortuosity.
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where k is the Boltzmann constant, T is body temperature, μ is fluid viscosity and R
is the hydrodynamic molecule radius.
Conclusions and future work
The shortcomings from PTCA and BMS procedures have been well documented since
the devices became a prominent treatment of choice for interventional cardiologists in
patients with severely stenosed coronary arteries. The underlying pathology of events
such as restenosis have been investigated and it is widely accepted that proliferation of
SMC from the medial layer of the artery to the site of injury is the primary cause of
recurring ischemic events. Restenosis is regarded as a catastrophic failure for cardiovas-
cular devices such as stents as it increases cost and trauma to the patient and can
cause death if left untreated. The application of anti-proliferative agents on the surface
of the stent introduced a greater degree of control that had been lacking in the first
generation BMS. Quantification and associated predictive modelling of drug distribu-
tion from a DES in order to better understand the influence of arterial variables on
MT is essential. This can only be achieved with realistic experimental validation of
mass transport within a porous media for a range of compressive values. A more com-
prehensive understanding of the influences of such variables could lead to an optimal
DES design which could provide a uniform distribution of drugs within the artery for a
patient specific stenosis.
The therapeutic potential of a DES rests with its ability to distribute drugs evenly
within the artery. Histological studies of excised stented arteries clearly depict arterial
compression beneath stent struts [38]. Promising results from the thinner strut
Xience-V stent in the SPIRIT-III clinical trials may explain the extent to which a
decrease in strut thickness can have a positive effect on the clinical outcome. Knowl-
edge of initial diffusivities for each of the constituent media is not enough when devel-
oping a predictive MT model of DES within a diseased artery. An iterative method
taking into account the effect of stent strut compression on arterial diffusivity is
required if a comprehensive understanding is to be achieved. Such improved numerical
models of drug diffusion in arteries will lead to the development of favourable deploy-
ment conditions, responsible for the amount of artery wall compression, along with
the development of desired drug properties which would enable the DES to deliver
therapeutic quantities of drug to the artery wall as efficiently as possible.
It is evident that DES have made a major contribution to minimally invasive inter-
ventional cardiology by significantly reducing restenosis rates. A lack of knowledge
regarding the mechanisms of drug transfer from these devices once implanted led DES
developers to take a top-down approach to treating the problem. The stents were
coated with ‘enough’ toxic drugs to combat restenosis and would give a beneficial
response. This method had a clear commercial advantage over a slower bottom-up
stent design approach, where all factors influencing MT would be assessed and taken
into account during the DES design stage. Since their conception it has been the
greater research community that has driven the increase in the knowledge base regard-
ing MT from DES. This paper introduces the issue of compression mediating artery
wall MT that has to date been overlooked in DES studies.
O’Connell and Walsh [62] examined this effect in an analogous experimental model and
found a 35% decrease in effective diffusivity within the porous wall when it was
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compressed by 23.75%. Although their experiment was only a 1-D validation it gave
insight into how compression can play an important role in regulating drug distribution
within the artery wall. There are two main causes of concern associated with excessive
artery wall compression. Firstly by reducing the artery wall diffusivity the drugs fail to dis-
tribute sufficiently throughout the artery wall, resulting in a concentrated dose of drugs
beneath the stent strut. Secondly this excessive drug pooling can have a toxic effect on the
artery wall. A study by Cho et al. in 2006 [66] reported on the ability of paclitaxel to
inhibit human SMC proliferation with concentrations as low as 0.1 × 10-3 mol m-3 to a
maximum of 1 × 10-3 mol m-3. However, at the higher concentrations of paclitaxel a
decrease in the proliferative activity of human endothelial cells was witnessed. Re-endothe-
lialisation is a desired response after DES implantation and the pooling of drugs beneath
the stent struts may adversely affect this process.
If a range of deployment conditions for a given stent design were known prior to
implantation then a drug with a desired artery wall diffusivity could be allocated and
loaded onto a polymer with the appropriate release characteristics. Likewise if a speci-
fic drug had to be delivered without compromising its diffusivity value then the stent
design could be changed so as to minimise the damage/compression on the artery. As
the hypothesis of compression mediating porous mass transport from DES is in its
infancy there remains a substantial amount of work to first validate it in a 3-D arterial
environment and subsequently model it computationally with the inclusion of the find-
ings from previous studies. Ongoing studies to address these issues would ultimately
result in the completion of a bottom-up understanding of the fundamentals of drug
MT from a DES.
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